Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X, Kosinski JR, Lao J, Shen X, Petrov A, Chicchi GG, Eiermann GJ, Pocai A. Du X, et al. Among authors: lao j. Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E265-71. doi: 10.1152/ajpendo.00142.2012. Epub 2012 May 22. Am J Physiol Endocrinol Metab. 2012. PMID: 22621866 Free article.
Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice.
More VR, Lao J, McLaren DG, Cumiskey AM, Murphy BA, Chen Y, Previs S, Stout S, Patel R, Satapati S, Li W, Kowalik E, Szeto D, Nawrocki A, Pocai A, Wang L, Carrington P. More VR, et al. Among authors: lao j. PLoS One. 2017 Oct 24;12(10):e0186586. doi: 10.1371/journal.pone.0186586. eCollection 2017. PLoS One. 2017. PMID: 29065174 Free PMC article.
Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists.
Wu M, Carballo-Jane E, Zhou H, Zafian P, Dai G, Liu M, Lao J, Kelly T, Shao D, Gorski J, Pissarnitski D, Kekec A, Chen Y, Previs SF, Scapin G, Gomez-Llorente Y, Hollingsworth SA, Yan L, Feng D, Huo P, Walford G, Erion MD, Kelley DE, Lin S, Mu J. Wu M, et al. Among authors: lao j. Nat Commun. 2022 Feb 17;13(1):942. doi: 10.1038/s41467-022-28561-9. Nat Commun. 2022. PMID: 35177603 Free PMC article.
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP. Fong TM, et al. Among authors: lao j. J Pharmacol Exp Ther. 2007 Jun;321(3):1013-22. doi: 10.1124/jpet.106.118737. Epub 2007 Feb 27. J Pharmacol Exp Ther. 2007. PMID: 17327489
Mapping Lipogenic Flux: A Gold LDI-MS Approach for Imaging Neutral Lipid Kinetics.
Downes DP, Zhong W, Zhang J, Chen B, Satapati S, Metzger D, Godinez G, Lao J, Sheth PR, McLaren DG, Talukdar S, Previs SF. Downes DP, et al. Among authors: lao j. J Am Soc Mass Spectrom. 2020 Dec 2;31(12):2421-2425. doi: 10.1021/jasms.0c00199. Epub 2020 Sep 1. J Am Soc Mass Spectrom. 2020. PMID: 32840373
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, Shen CP, Lao J, Xiao JC, Shearman LP, Stribling DS, Rosko K, Strack A, Marsh DJ, Feng Y, Kumar S, Samuel K, Yin W, Van der Ploeg LH, Goulet MT, Hagmann WK. Lin LS, et al. Among authors: lao j. J Med Chem. 2006 Dec 28;49(26):7584-7. doi: 10.1021/jm060996+. J Med Chem. 2006. PMID: 17181138
447 results